Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study tests an experimental drug called TQ05105 in people with a rare bone marrow cancer called myelofibrosis. The trial includes 51 adults whose disease is at intermediate or high risk and who have not responded to or cannot tolerate standard JAK inhibitor therapy. The main…

This study tests a new medicine called TQH3906 in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The goal is to see if the drug can reduce lupus activity and improve symptoms better than a placebo. About 198 adults with SLE will take either TQH3906 …

This study tests a new oral drug, TQB3201, in people with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The drug works by breaking down the androgen receptor, which fuels cancer growth. The trial aims to find the safest dose and chec…

This early-stage study tests a new tablet called TQB3217 in about 40 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Researchers will also look …

This early-stage trial tests a new drug called TQB3142 in 66 adults with advanced solid tumors who have run out of standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look fo…

This study tests whether a combination of intravenous and inhaled polymyxin E2 can safely treat pneumonia caused by carbapenem-resistant bacteria in hospitalized or ventilated patients. About 48 adults will receive either the experimental treatment or a control. The goal is to se…

This early-stage study looks at how the drug anecatibin fumarate behaves in people with lung cancer who have different levels of liver function. Researchers will compare drug levels and safety in 24 adults with either impaired or normal liver function. The goal is to understand i…